Juno Therapeutics (JUNO) Shows Positive Early Data In Leukemia Patients

Looking Forward

The JUNO stock should see a lot of trade volume on Monday because of the release of these results. There will be many buyers that will be bullish on the results themselves, however there will be a lot of bears as well. The bear side will argue that despite stellar results there were patients who experienced severe toxicity taking JCAR014. That means that the stock will be hard pressed to post any gains if at all.

As long as the clinical hold issue continues to plague JUNO it will be hard for it trade higher. When the company itself announced its voluntary hold on JCAR017 the stock tanked by 37% in one day. Investors must hope that the CAR-T toxicity doesn’t translate to other trials including the JCAR014 program.

If that were to happen the stock could fall further sending shares of JUNO to new 52-week lows. The stock currently trades at $20.43 per share which is close to its 52-week low of $19.41 per share. A breach of the 52-week low could cause the stock to trade lower, and is something that traders should watch for.

If the voluntary clinical hold is lifted, then there is a possibility the stock could recover over time. It won’t reach its 52-week high of $52.62 per share anytime soon, but pending positive clinical outcomes overtime it may eventually get there. Again, this is only if the company’s CAR-T issues don’t get worse.

1 2 3
View single page >> |

Disclosure: None

How did you like this article? Let us know so we can better customize your reading experience.


Leave a comment to automatically be entered into our contest to win a free Echo Show.